Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

POU5F1B is responsible for the acquired resistance to dabrafenib in papillary thyroid cancer cells with the BRAF V600E mutation.

Endocrine - 1 Jan 2025

Li Jun, Yu Yafeng

Abstract excerpt

BACKGROUND: Dabrafenib, an inhibitor of the B-Raf proto-oncogene (BRAF) V600E mutant, has become the major drug for targeted therapy of papillary thyroid cancer (PTC) with the BRAF V600E mutant; however, acquired resistance is inevitable. OBJECTIVE: To identify key transcription factors (TFs) involved in dabrafenib resistance and identify targets to reverse dabrafenib resistance. METHODS: Dabrafenib-resistant PTC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Imidazoles
Share to Octamer Transcription Factor-3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oximes

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 39136897
DOI: 10.1007/s12020-024-03994-y

Genes

POU5F1B
BRAF
TF
E2F2
FOXO4
FOXP3
TBX4
WNT4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

POU5F1B is responsible for the acquired resistance to dabrafenib in papillary thyroid cancer cells with the BRAF V600E mutation.PMID 39136897Read ↗

Silencing FOXP2 reverses vemurafenib resistance in BRAFV600E mutant papillary thyroid cancer and melanoma cells.Semantic proximity Read ↗

RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer PatientSemantic proximity Read ↗

PHGDH inhibition overcomes dabrafenib resistance through metabolic rewiring in BRAF V600E anaplastic thyroid carcinomaSemantic proximity Read ↗

Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer.Semantic proximity Read ↗

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung CancersSemantic proximity Read ↗

A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancerSemantic proximity Read ↗

Integrative analysis of multi-omics data reveals inhibition of RB1 signaling promotes apatinib resistance of hepatocellular carcinomaSemantic proximity Read ↗

Understanding and overcoming innate and acquired MAPK-inhibition resistance in anaplastic thyroid cancerSemantic proximity Read ↗

Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistanceSemantic proximity Read ↗

COL5A2 drives regorafenib resistance-induced metastatic phenotype via reducing LIFR expression in hepatocellular carcinoma.Semantic proximity Read ↗

Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.Semantic proximity Read ↗

Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.